Indefinite Delivery Contract 75D30124D19080
Award Date
7/1/24
Last Date to Order
6/30/25
Federal Agency
CDC Pittsburgh
Awardee
Glaxosmithkline, LLC
Ultimate Awardee
Not listed
NAICS Category
325412 - Pharmaceutical Preparation Manufacturing
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Pricing Type
Firm Fixed Price
Legislative Mandate
Not listed
National Interest Action
None
Award Type
Multiple
Primary Consortia Member
Not listed
Similar IDVs
This indefinite-delivery, indefinite-quantity (IDIQ) contract was awarded by the Centers for Disease Control and Prevention (CDC), National Center for Immunization and Respiratory Diseases, to Glaxosmithkline, LLC, a pharmaceutical company, for the purchase of 12 standard adult vaccines. The $172.4 million contract has a one-year period of performance from July 1, 2022 to June 30, 2023 and does not utilize any set-asides. The vaccines, which include influenza, hepatitis, pneumococcal, and...
This indefinite delivery contract (IDC) was awarded by the Centers for Disease Control and Prevention (CDC) to Glaxosmithkline, LLC, a foreign-owned, for-profit pharmaceutical company, to supply a variety of adult vaccines over a one-year period from July 1, 2023 through June 30, 2024. The total contract ceiling value is $232,487,206.61. The contract covers the procurement of an estimated 1.5 to 3 million doses of 12 different adult vaccines, including hepatitis A, hepatitis B, hepatitis A &...
The Centers for Disease Control and Prevention (CDC), National Center for Immunization and Respiratory Diseases (NCIRD) awarded an Indefinite Delivery/Indefinite Quantity (ID/IQ) contract to Bavarian Nordic, Inc. for the procurement of various adult vaccines. The $99,015,000 multiple-award contract has a period of performance from July 1, 2024 to June 30, 2025. The contract does not utilize any set-asides. The solicitation seeks the purchase of vaccines for Hepatitis A, Hepatitis B, Hepatitis...
The Centers for Disease Control and Prevention (CDC) has awarded an Indefinite Delivery, Indefinite Quantity (IDIQ) contract to Dynavax Technologies Corporation, valued at up to $56,203,651.08, to supply various adult vaccines over a one-year period from July 1, 2023 through June 30, 2024. The vaccines to be delivered include hepatitis A, hepatitis B, hepatitis A & B combination, pneumococcal polysaccharide, tetanus and diphtheria toxoids, herpes zoster, tetanus, reduced diphtheria toxoid...
The Centers for Disease Control and Prevention awarded multiple indefinite-delivery, indefinite-quantity contracts valued at up to $25,350,000 to supply adult vaccines for the period of July 1, 2023 through June 30, 2024. The prime contractor is VBI Vaccines (Delaware) Inc. The contracts aim to procure minimum and maximum quantities of 12 adult vaccines, including hepatitis A, hepatitis B, pneumococcal polysaccharide, tetanus and diphtheria toxoids, herpes zoster, measles, mumps and rubella,...
The Centers for Disease Control and Prevention (CDC) has awarded a 5-year, multiple-award Indefinite Delivery Contract (IDC) to Sanofi Pasteur Inc. for the purchase of various adult vaccines. The contract has a ceiling value of $54,975,837.60 and covers the period from July 1, 2024 to June 30, 2025, with the possibility of subsequent option years. As the prime contractor, Sanofi Pasteur Inc. will provide a range of vaccines including Hepatitis A, Hepatitis B, Hepatitis A&B combination,...
The Centers for Disease Control and Prevention (CDC) has awarded a $56.2 million Indefinite Delivery Indefinite Quantity (IDIQ) contract to Dynavax Technologies Corporation, a biopharmaceutical company, for the purchase of 12 standard adult vaccines. This contract will support the CDC's immunization awardees, including state health departments, in their adult immunization programs authorized under Section 317(j) of the Public Health Service Act. The contract has a one-year period of...
The Centers for Disease Control and Prevention (CDC), National Center for Immunization and Respiratory Diseases (NCIRD) awarded an Indefinite Delivery Indefinite Quantity (IDIQ) contract worth up to $58,450,000 to Dynavax Technologies Corporation (Dynavax) for the purchase of various adult vaccines. The contract has a period of performance from July 1, 2024 to June 30, 2025 and is not set-aside. The required vaccine types include Hepatitis A, Hepatitis B, Hepatitis A&B combination, Herpes...
The Centers for Disease Control and Prevention (CDC) has awarded Pfizer Inc. an Indefinite Delivery Contract (IDC) for the supply of various adult vaccines to support immunization programs under Section 317(j) of the Public Health Service Act. The $103,060,230.33 contract, which runs from July 1, 2023 to June 30, 2024, covers a range of vaccines including hepatitis A, hepatitis B, pneumococcal polysaccharide, tetanus and diphtheria toxoids, herpes zoster, measles-mumps-rubella, meningococcal...
The Centers for Disease Control and Prevention (CDC), National Center for Immunization and Respiratory Diseases (NCIRD) awarded an indefinite-delivery, indefinite-quantity (IDIQ) contract to Merck Sharp & Dohme LLC, doing business as Merck, for the supply of various adult vaccines. The contract has a potential value of $87,753,075 and a period of performance from July 1, 2023 through June 30, 2024. The vaccines will be delivered within 15 business days of order receipt and shipped FOB...